中国医药品牌怎么样 申请店铺

我要投票 中国医药在化学药物行业中的票数:91 更新时间:2025-02-02
中国医药是哪个国家的品牌?「中国医药」是 中国医药集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人佘鲁林在1987-03-26期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中国医药怎么样

中国医药健康产业股份有限公司是在上海证券交易所挂牌的国有控股上市公司(股票简称:中国医药;证券代码:600056),其控股股东为中央骨干企业中国通用技术(集团)控股有限公司。公司秉承“关爱生命、追求卓越”的核心理念,致力于医药产业发展和人类健康事业,努力打造中国医药领域的旗舰企业。

公司已经建立起了以国际贸易为引领、以医药工业为支撑、以医药商业为纽带的科工贸一体化产业格局,产业形态涉及研发、种植加工、生产、分销、物流、进出口贸易、学术推广、技术服务等全产业链条。

在医药研发生产领域,公司拥有两家博士后科研工作站及一大批高素质研发专家,曾获国家科技进步二等奖;公司拥有国内领先的化学原料药研发生产平台,国内先进的特色化学药、现代中药研发生产平台,在抗感染类、抗病毒类药物的研发生产及甘草等药材及其制品的种植加工领域处于领先地位。

在国际贸易领域,作为医药行业进出口领域传统专业主渠道,公司始终保持着领先地位,且在政府项目业务领域具备传统实力和特色优势。天然药物贸易业务坚持全产业链专业化发展模式,有机整合天然药物种植、仓储、加工、销售等产业链环节,在行业内居于领先地位。医药化工贸易业务经营范围涵盖化学原料及制剂、生物及血液制品各品规、全领域,可为客户提供一流的医药化工贸易集成服务。医疗器械贸易业务致力于为客户提供全过程项目集成化服务,并与世界各著名医疗器械生产商建立了稳固的合作关系,在进口和分销领域处于国内领先地位。健康领域大宗商品业务涉及保健食品原料、大宗农产品、精细化工原材料等,在一些重点商品进出口贸易领域有较高知名度。

在国内医药商业领域,公司已逐步建立起以高端、特色产品为核心,具有产业价值链整合协同优势的医药商业体系。已形成以北京、广东、江西、河南、河北、湖北、新疆为重点,覆盖全国的营销网络体系,并在所在区域具有较高的知名度和品牌影响力。公司建有大型物流中心,具备完善的经营资质,可为广大合作伙伴提供全方位的增值服务。

面向未来,中国医药着力在重点产品领域建立横跨国内和国际两个市场的营销网络,聚焦现代中药、特色化学制剂和生物制药等核心产业领域,打造集研发、生产、销售、服务于一体的产业链,努力将公司发展成为一家在国内医药行业中具有重要地位、在国际市场具有较强竞争力和品牌影响力的科工贸一体化大型医药企业集团。



China Pharmaceutical and Health Industry Co., Ltd. is a state-owned holding listed company (stock abbreviation: China Pharmaceutical; securities code: 600056) listed on Shanghai Stock Exchange. Its controlling shareholder is China General Technology (Group) Holding Co., Ltd., a central backbone enterprise. Adhering to the core concept of "caring for life and pursuing excellence", the company is committed to the development of pharmaceutical industry and human health, striving to build a flagship enterprise in the field of Chinese medicine. The company has established an integrated industrial pattern of science, industry and trade with international trade as the guide, pharmaceutical industry as the support and pharmaceutical business as the link. The industrial pattern involves the whole industrial chain of R & D, planting and processing, production, distribution, logistics, import and export trade, academic promotion, technical services, etc. In the field of pharmaceutical R & D and production, the company has two postdoctoral research stations and a large number of high-quality R & D experts, who have won the second prize of national science and technology progress; the company has a leading R & D and production platform for chemical raw materials, domestic advanced characteristic chemical drugs, modern Chinese medicine research and development production platform, in the R & D and production of anti infective and anti viral drugs, licorice and other medicinal materials The planting and processing field of products is in a leading position. In the field of international trade, as the traditional professional main channel in the field of import and export of pharmaceutical industry, the company has always maintained a leading position, and has traditional strength and characteristic advantages in the field of government project business. The natural medicine trade business adheres to the whole industrial chain specialized development mode, organically integrates the natural medicine planting, storage, processing, sales and other industrial chain links, and takes the leading position in the industry. The business scope of pharmaceutical and chemical trade covers chemical raw materials and preparations, biological and blood products, and all fields. It can provide customers with first-class integrated pharmaceutical and chemical trade services. The medical device trade business is committed to providing customers with the whole process of project integration services, and has established a solid cooperative relationship with the world's famous medical device manufacturers, and is in the leading position in the field of import and distribution in China. The bulk commodity business in the health sector involves health food raw materials, bulk agricultural products, fine chemical raw materials, etc., and has a high reputation in the import and export trade of some key commodities. In the field of domestic pharmaceutical business, the company has gradually established a pharmaceutical business system with high-end, characteristic products as the core and industrial value chain integration and coordination advantages. It has formed a marketing network system focusing on Beijing, Guangdong, Jiangxi, Henan, Hebei, Hubei and Xinjiang, covering the whole country, and has a high visibility and brand influence in its region. The company has built a large-scale logistics center with perfect business qualification, which can provide all-round value-added services for the vast number of partners. Facing the future, China Pharmaceutical focuses on establishing a marketing network across the domestic and international markets in key product areas, focusing on core industries such as modern Chinese medicine, characteristic chemicals and biopharmaceuticals, creating an industrial chain integrating R & D, production, sales and service, and striving to develop the company into a company with an important position in the domestic pharmaceutical industry and in the international market A large pharmaceutical enterprise group with strong competitiveness and brand influence.

本文链接: https://brand.waitui.com/755334abf.html 联系电话:01082287727

千城特选小程序码

7×24h 快讯

加拿大总理特鲁多表示,将对价值1550亿加元的美国商品征收25%的关税

加拿大总理特鲁多表示,加拿大将对价值1550亿加元的美国商品征收25%的关税。从周二起立即对价值300亿加元的商品征收关税。(财联社)

29分钟前

英特尔:为DeepSeek大模型提供优化工具,降低部署门槛

近日,DeepSeek推出了一款名为Janus Pro的先进AIGC(人工智能生成内容)模型,该模型以其卓越的性能和高精度引起了行业的广泛关注。2月2日,英特尔方面表示,英特尔® Gaudi 2D AI加速器针对Janus Pro进行了优化,为AI开发者提供了以更低的成本和更高的效率部署复杂任务的可能性,满足了行业对于推理计算能力的需求。(新浪财经)

29分钟前

商务部新闻发言人就美方宣布对中国输美产品加征10%关税发表谈话

美国东部时间2月1日晚8时许,美白宫发布事实清单,宣布以芬太尼等问题为由对中国输美产品加征10%关税。中方对此强烈不满,坚决反对。美方单边加征关税的做法严重违反世贸组织规则,不仅无益于解决自身问题,也对中美正常经贸合作造成破坏。对于美方的错误做法,中方将向世贸组织提起诉讼,并将采取相应反制措施坚定维护自身权益。中方希望美方客观、理性看待和处理自身芬太尼等问题,而不是动辄以关税手段威胁他国。中方敦促美方纠正错误做法,与中方相向而行,在平等互利、相互尊重基础上,直面问题,坦诚对话,加强合作,管控分歧。(商务部新闻办公室)

29分钟前

鸿蒙智行1月全系交付新车34987辆

据鸿蒙智行官方,2025年2月1日,鸿蒙智行2025年首月销量新鲜出炉,凭借着在在中高端市场的持续发力,1月全系交付新车34987辆,实现了新年首月销量的开门红。

29分钟前

保险业2024年原保险保费收入约5.7万亿元

国家金融监督管理总局发布的数据显示,2024年,中国保险业原保险保费收入约5.7万亿元,其中财产险1.43万亿元、人身险4.26万亿元。在赔付方面,2024年中国保险业原保险赔付支出2.3万亿元,其中财产险9810亿元、人身险1.32万亿元。截至2024年末,中国保险业总资产35.9万亿元,净资产3.32万亿元。(财联社)

29分钟前

本页详细列出关于易乎生物的品牌信息,含品牌所属公司介绍,易乎生物所处行业的品牌地位及优势。
咨询